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Dominant Lethal Studies with the
Halogenated Olefins Vinyl Chloride
and Vinylidene Dichloride in Male
CD-i Mice
by Diana Anderson,* M. C. E. Hodge,* and
1. F. H. Purchase*
The mutagenic activity ofvinyl chloride (VC) and vinylidene dichloride (VDC) at three exposure levels
was assessed in fertile male CD-I mice with the dominant lethal test. Each compound was assessed in a
separate study.
Male mice were exposed by inhalation to VC at 3000, 10,000, and 30,000 ppm and to VDC at 10, 30,
and 50 ppm for 6 hr/day for 5 days. By comparison with control malesexposed to air, no mutagenic effects
on any maturation stage of spermatogenesis in treated males were detected. There was no significant
increase in the number ofpostimplantational early fetal deaths as shown by the number of females with
one or more early deaths or the number of early deaths/pregnancy or the number of early deaths/total
implants/pregnancy. There was no evidence of pre-implantational egg losses as indicated by the total
implants/pregnant female. There was also no reduction in fertility. (The reduction in fertility at 50 ppm
VDC was unproven).
The lack ofeffect was not due to the insensitivity ofthe system used, since both the VC and VDC study a
mutagenic effect was clearly demonstrated in male mice dosed IP with the positive control compounds
cyclophosphamide (CTX) and/or ethylmethane sulfonate (EMS). During dosing these animals were
housed under similar exposure conditions to those animals exposed to the test substances but with a flow
of air through the exposure chambers.
Thus, neither VC nor VDC is mutagenic in the mouse at the stated exposure levels as measured by the
dominant lethal test.
Introduction
VC used in the manufacture of poly(vinyl
chloride) has been found to cause tumors in rats (1)
and man (2). It has also been shown to produce
chromosome breaks in exposed workers (3-6) and
causes mutations in Salmonella typhimurium (7, 8).
Another chlorinated monomer, VDC is also known
to cause mutation in Salmonella typhimurium (7,8).
We, therefore, carried out dominant lethal studies
to determine if there were any mutagenic effects of
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this type in mice after VC and VDC exposure at
three levels. At the same time negative control ani-
mals exposed to air and positive control animals
also exposed to air and given EMS and/or CTX
were assayed.
Materials and Methods
Chemicals
VC was obtained from Air Products Ltd., Wors-
ley, Walkden, Lancs., U.K. VDC was obtained
from ICI Ltd., Mond Division, Runcorn, Cheshire,
U.K. EMS was obtained from Koch-Light Ltd.,
Colnbrook, Bucks, U.K., and CTX (Endoxalra)
from Ward Blenkinsop Ltd., London, U.K.
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CD-I mice (Charles River, Manston, Kent) were
used throughout the experiment. Undosed females
were 8-10 weeks old when mated and male mice
immediately after dosing were 10-12 weeks old.
Males were caged individually and females in pairs.
They received food and water ad libitum.
Dosing of Male Mice
Dose levels for VC and VDC were selected on
the basis of preliminary toxicity studies. A dose of
30,000 ppm of VC was found to be in the toxic
range and this was chosen as the highest exposure
level since it was desirable that the maximum toler-
ated dose or higher should be used. Other levels of
10,000 and 3000 ppm were also used. The required
concentrations of VC were generated by mixing
known volumes of VC and compressed air using
rotameters as indicators. VDC was much more
toxic to the mice. Exposure levels of50, 30, and 10
ppm were selected. The required concentrations of
VDC were generated by a controlled fluid-
feed/atomizer technique (9). The method involves
continuously passing a known volume of the com-
pound through a concentricjet atomizer, where it is
vaporized by a calculated volume of dry clean air.
The volume of air required as calculated from Eq.
(1).
Air flow (1./min) =
Syringe size (mi/cm) x density (g/ml) x 24 x 106
Injection rate (min/cm) x ppm x mol. wt.
During dosing the mice were housed individually
in chambers made of stainless steel and glass with
an internal capacity of three litres.
Most of the negative control animals and all ani-
mals dosed with CTX or EMS were housed under
identical conditions during the dosing period but
with a flow of air through the chambers. Those
dosed with CTX were injected IP on day 5 of ex-
posure and those dosed with EMS were given an
oral dose by gavage for 5 consecutive days. Both of
these substances were prepared as aqueous solu-
tions immediately before use. Some of the animals
in the negative control group controlling the VDC
study were housed undernormal conditions. Before
test mating began, groups of mice were treated as
shown in Table 1.
In the VDC study, in order to obtain agroup with
sufficient animal numbers some of the animals
which were infertile in week 0 were included in
group 4. Of the 8 survivors, 5 did not mate in the
fertility study and one had a higher than average
number of early deaths. However some of these
males mated in the main study. One male surviving
50 ppm for 2 days died in week 2 of the study. Of
the 17 animals, three in the CTX treatment group
also did not mate in the fertility study. Fifty animals
were included in the negative control group to pro-
vide abetter data base against which to compare the
treated groups. There were no statistical differ-
ences between males exposed to air and housed
under normal conditions.
Mating
Fertility Testing. Male mice were caged with
virgin female mice, 1 male and 2 female mice in
Table 1. Treatment groups.
No. survivors/
no. animals treated
Group (mice) Treatment
VC Study
Group 1 20/20 Air (negative control)
Group 2 18/20 3000 ppm VC, 6 hr/day, 5 days
Group 3 19/20 10,000 ppm VC, 6 hr/day, 5 days
Group 4 9/20 30,000 ppm VC, 6 hr/day, 5 days
Group 5 15/15 200 mg CTX in water/kg body weight, once by IP
injection on day 5.
Group 6 25/25 200 mg EMS in water/kg
body weight orally, once/day, 5 days
VDC Study
Group 1 50/50 15 air, 35 normal conditions (negative control)
Group 2 20/20 10 ppm VDC, 6 hr/day, 5 days
Group 3 18/20 30 ppm VDC, 6 hr/day, 5 days
Group 4 6/20 50 ppm VDC, 6 hr/day, 2 days
2/20 75 ppm VDC, 6 hr/day for 1 day, then
50 ppm VDC, 6 hr/day, for 1 day
Group 5 17/17 200 mg CTX in water/kg body weight, once by IP
injection on day 5
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ferred to other cages. The female mice were killed
15 days after first introducing them to the males and
examined for pregnancies. The 106 males which
survived dosing in the VC study and 113 males in
the VDC study and were successful in fertilizing at
least 1 female in their cage were selected for con-
tinuation in the experiment.
Experimental Mating. Two virgin female mice
8-10 weeks old were put into each of the 106 and
113 cages in which the males were individually
housed. After 5 days the females were removed and
rehoused in pairs. A week after the initial introduc-
tion the males were caged with another two virgin
females and again left for 5 days. This process was
repeated until the treated male mice had been mated
at weekly intervals for 8 weeks with virgin females.
The males were then killed and not examined
further. No attempts were made to establish
whether or when mating had occurred. Instead it
was assumed that most matings leading to fertiliza-
tion would occur 2 or 3 days after introducing
female mice to the cages containing males.
Female mice were killed 13 days after the as-
sumed date of fertilization, i.e., 15 or 16 days after
caging females with males.
Assessment
Uteri of killed mice were examined for live im-
plantations, early deaths, and late deatl's.
Statistics
The data have been statistically analyzed as re-
ported previously (10).
Results
Mating weeks after treatment are represented in
Tables 2-13 by numbers 1-8 and the mating week
before treatment is represented by week 0. As-
sessment of females which became pregnant during
the fertility test yielded the data for week 0 but only
data from those animals that survived treatment
have been included in weeks 0-8. Tables 2-7 relate
to the VC study and Tables 8-13 relate to the VDC
study.
Table 2. Number and percentage of male mice which survived treatment successfully mating at each week.
Group 1, Group 2. Group 3, Group 4, Group 5, Group 6,
air VC, VC, VC, CTX, EMS,
(negative 3,000 ppm 10,000 ppm 30,000 ppm 200 mg/kg 200 mg/kg
control) (6 hr x 5) (6 hr x 5) (6 hr x 5) p (oral) x 5
Week No. of % No. of % No. of 7 No. of % No. of % No. of %
mice mice mice mice mice mice
0 20 100 18 100 19 100 9 100 15 100 25 100
1 20 100 18 100 18 100 7 77.8 14 93.3 3' 12.2
2 20 100 18 100 19 100 9 100 14 93.3 23 92.0
3 20 100 18 100 19 100 9 100 14 93.3 23 92.0
4 20 100 18 100 19 100 9 100 15 100 25 100
5 19 95.0 18 100 19 100 7 77.8 15 100 25 100
6 20 100 18 100 19 100 9 100 14 100 24 100
7 20 100 18 100 19 100 9 100 14 93.3 25 100
8 20 100 18 100 19 100 8 88.9 13 92.9 25 100
"lp < 0.001.
Table 3. Number of mated females becoming pregnant.
Group 1, Group 2, Group 3, Group 4, Group 5, Group 6.
air VC, VC, VC, CTX, EMS,
(negative 3,000 ppm 10,000 ppm 30,000 ppm 200 mg/kg 200 mg/kg
control) (6 hr x 5) (6 hr x 5) (6 hr x 5) Ip (oral) x 5
Week No. No. No. No. No. No. No. No. No. No. No. No.
pregnant mated pregnant mated pregnant mated pregnant mated pregnant mated pregnant mated
0 35 40 30 36 28 38 15 18 25 30 37 50
1 35 40 33 36 32 36 11 18 26 30 4"1 50
2 36 40 36 36 33 38 15 18 25 30 31" 50
3 34 40 30 36 34 38 16 18 26 30 40 50
4 38 40 34 36 33 38 17 18 30 30 46 50
5 35 40 34 36 36 38 12 18 28 30 47 50
6 36 40 33 36 36 38 18 18 26 28 47 48
7 37 40 31 36 37 38 18 18 22 30 41 50
8 37 40 32 36 31 37 14 18 23 28 45 50
atp < 0.001. bp <0.01.
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Group 1, Group 2, Group 3, Group 4, Group 5, Group 6.
air VC VC, VC, CTX, EMS,
(negative 3,000 ppm 10,000 ppm 30,000 ppm 200 mg/kg 200 mg/kg
Week control) (6 hr x 5) (6 hr x 5) (6 hr x 5) IP (oral) x 5
0 11.9 12.6 12.0 13.0 11.3 11.8
1 12.9 13.6 13.4 16.1 8.8" 4.0"
2 12.8 12.7 13.0 13.7 10.9 8.4"
3 12.5 12.5 12.4 11.2 10.9 12.5
4 12.4 12.1 13.7 10.0" 12.6 12.7
5 13.7 12.7 14.1 12.8 12.3 12.7
6 11.7 11.9 12.5 12.6 12.5 12.1
7 11.8 11.6 11.8 12.0 11.5 12.4
8 12.7 12.1 12.6 12.1 12.5 12.5
0p < 0.01.
bp < 0.05.
Table 5. Number of pregnant females with one or more early deaths (ED).
Group 1, Group 2, Group 3, Group 4, Group 5. Group 6,
air VC, VC, VC, CTX. EMS,
(negative 3,000 ppm 10,000 ppm 30,000 ppm 200 mg/kg 200 mg/kg
control) (6 hr x 5) (6 hr x 5) (6 hr x 5) IP (oral) x 5
Week
0 I ED 0 1 ED 0 1 ED 0 I ED 0 I ED 0 I ED
0 18 17 21 9 16 22 10 5 22 3a 21 26
1 15 20 16 17 10 21 6 5 1 25" 1 3
2 19 17 18 18 13 20 6 9 2 23a 5 26"
3 18 16 16 14 19 15 9 6 8 18 15 25
4 16 22 17 17 20 13 9 7 14 16 19 27
5 17 18 18 16 14 22 3 9 12 16 25 22
6 17 19 11 22 21 15 7 11 13 13 24 23
7 18 19 13 18 21 16 8 10 10 12 22 19
8 13 24 14 18 15 16 8 6 13 10 22 23
ap < 0.01.
Table 6. Mean number of early deaths per pregnancy.
Group 1, Group 2, Group 3, Group 4, Group 5, Group 6,
air VC, VC, VC, CTX, EMS,
(negative 3,000 ppm 10,000 ppm 30,000 ppm 200 mg/kg 200 mg/kg
Week control) (6 hr x 5) (6 hr x 5) (6 hr x 5) IP (oral) x 5
0 0.77 0.33 0.54 0.40 0.16 0.59
1 0.86 0.91 1.00 0.45 4.27a 3.50a
2 0.83 1.00 1.15 0.93 4.84a 2.58a
3 0.91 0.73 0.88 0.93 1.54 1.45
4 0.89 0.79 0.61 0.69 1.13 0.85
5 1.06 0.71 1.03 1.00 1.11 0.72
6 0.97 0.91 0.75 1.39 0.65 0.85
7 0.76 0.87 0.68 0.89 0.82 0.63
8 1.03 0.88 1.00 0.71 0.70 0.73
ap < 0.01.
Table 7. Early deaths as a percentage of total implants per pregnant female.
Group 1, Group 2, Group 3, Group 4, Group 5, Group 6,
air VC, VC, VC, CTX, EMS,
(negative 3,000 ppm 10,000 ppm 30,000 ppm 200 mg/kg 200 mg/kg
Week control) (6 hr x 5) (6 hr x 5) (6 hr x 5) IP (oral) x 5
0 6.5 2.7 4.4 3.1 1.4a 5.1
1 6.6 6.7 7.5 2.7 49.lb 77.78b
2 6.4 7.9 9.6 6.9 44.6b 31.5b
3 7.3 5.9 7.0 7.8 14.1 11.6
4 7.2 6.5 4.5 6.5 9.0 6.7
5 7.8 5.5 7.3 7.9 9.1 5.7
6 8.2 7.6 6.0 11.1 5.2 7.0
7 6.4 7.3 5.7 7.4 7.0 5.1
8 8.0 7.2 8.1 5.9 5.7 5.9
ap < 0.05.
bp < 0.01.
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Group 1 Group 2, Group 3, Group 4, Group 5,
(pooled VDC, VDC, VDC, CTX,
negative 10 ppm 30 ppm 50 ppm 200 mg/kg
control) (6 hr x 5) (6 hr x 5) (6 hr x 5) IP
Week No. of No. of No. of No. of No. of
mice % mice % mice % mice % mice %
0 50 100 20 100 18 100 8a 38 17b 76
1 50 98 20 95 18 100 8a 75 17b 65
2 -50 96 20 100 18 94 7b 86 16 94
3 50 94 20 100 18 89 7a 43 17 94
4 49 98 20 100 18 89 7" 43 15 100
5 47 94 20 100 17 82 7a 57 17 100
6 49 88 20 100 17 100 7a 43 17 88
7 49 92 20 90 17 100 6c 50 16c 75
8 48 92 19 95 17 88 7" 57 19 86
ap 0.001.
bp < 0.01.
cp < 0.05.
Table 9. Number of mated females becoming pregnant.
Group I Group 2, Group 3, Group 4, Group 5,
(pooled VDC, VDC, VDC, CTX,
negative 10 ppm 30 ppm 50 ppm 200 mg/kg
control) (6 hr x 5) (6 hr x 5) (6 hr x 5) IP
No. No. No. No. No. No. No. No. No. No.
Week pregnant mated pregnant mated pregnant mated pregnant mated pregnant mated
0 73 100 30 40 25 36 5a 16 17b 34
1 82 100 32 40 33 36 7a 16 20b 34
2 75 100 36 40 32 36 7a 14 25 33
3 82 100 34 40 26 36 5a 14 28 34
4 85 98 36 40 27 36 6b 14 26 32
5 80 94 34 40 26 34 6a 14 29 34
6 75 98 33 40 32 34 5b 14 25 34
7 77 98 33 40 28 34 7 13 19C 33
8 73 96 28 39 26 34 7 14 28 39
a p< 0.01.
b p < 0.001.
cp < 0.05.
Table 10. Mean total implants per pregnant female.
Group I Group 2, Group 3, Group 4, Group 5,
pooled VDC, VDC, VDC, CTX,
(negative 10 ppm 30 ppm 50 ppm 200 mg/kg
Week control) (6 hr x 5) (6 hr x 5) (6 hr x 5) IP
0 12.2 11.01' 12.0 11.4 11.5
1 12.3 13.1 12.8 11.7 9.2b
2 12.3 11.7 12.1 11.0 9.5
3 12.0 12.1 13.2 13.4 11.0L
4 12.0 12.1 13.0 12.7 12.1
5 11.8 11.7 12.5 10.7 12.0
6 12.5 12.4 12.1 12.6 1 1.1a
7 12.6 13.0 12.5 12.7 11.7c
8 12.3 13.6 12.4 12.6 11.6
"p <.0.01.
bp < 0.001.
cp < 0.05.
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Group 1 Group 2, Group 3, Group 4, Group 5,
(pooled VDC, VDC, VDC, CTX,
negative 10 ppm 30 ppm 50 ppm 200 mg/kg
control) (6 hr x 5) (6 hr x 5) (6 hr x 5) IP
Week 0 IED 0 1ED 0 I ED 0 1ED 0 I ED
0 40 33 14 16 10 15 1 4 9 8
1 41 41 18 14 19 14 6 1 0' 20
2 39 36 18 18 17 15 3 4 2" 23
3 45 37 18 16 15 11 4 1 7b 21
4 40 45 17 19 11 16 2 4 12 14
5 41 39 15 19 11 15 3 3 12 17
6 40 35 14 19 15 17 2 3 12 13
7 43 34 15 18 15 13 5 2 10 9
8 37 36 13 15 13 13 3 4 15 5
"p < 0.001.
bp < 0.01.
Table 12. Mean number of early deaths per pregnancy.
Group I Group 2, Group 3, Group 4, Group 5,
(pooled VDC, VDC, VDC, CTX,
negative 10 ppm 30 ppm 50 ppm 200 mg/kg
Week control) (6 hr x 5) (6 hr x 5) (6 hr x 5) IP
0 0.59 0.80 0.84 2.00 1.06
1 0.72 0.72 0.61 0.29 4.00"
2 0.69 0.75 0.56 0.71 - 4.04"
3 0.76 0.68 0.46 0.80- 2.32"
4 0.79 0.83 1.00 1.00 0.85
5 0.78 0.68 0.73 0.67 0.86
6 0.88 0.91 0.94 1.00 0.64
7 0.65 0.85 0.57 0.57 0.74
8 0.85 0.75 0.85 0.71 0.30
"p < 0.001.
Table 13. Early deaths as a percentage of total implants per pregnant female.
Group 1 Group 2, Group 3, Group 4, Group 5,
(pooled VDC, VDC, VDC, CTX,
Week negative 10 ppm 30 ppm 50 ppm 200 mg/kg
control) (6 hr x 5) (6 hr x 5) (6 hr x 5) IP
0 4.8 10.1 7.3 17.3 9.1
1 5.7 5.3 5.1 2.2 45.6"
2 5.5 6.9 4.4 5.7 41.4"
3 6.4 6.3 3.6 5.3 21.88
4 6.9 7.1 7.4 10.3 6.9
5 6.6 6.1 6.2 5.6 6.9
6 7.0 7.6 8.3 7.5 5.6
7 4.9 6.6 4.5 4.3 6.1
8 7.0 5.4 7.1 5.8 2.4
"p < 0.001.
Fertility
Successful Mating Frequency. The numbers
of males successfully mating at each week are
shown in Tables 2 and 8. Numbers remained high
during the experiments. No statistically significant
differences in the mating frequency were found be-
tween VC treatment groups and the control at any
week by using a chi-squared test. There was, how-
ever, a significant difference between the EMS-
treated group and the negative control group in
week 1. In the VDC study, the mating frequency
was high in the two groups exposed to the lowest
doses of VDC in all weeks by comparison with the
negative control group. The mating frequency,
however, was statistically significantly lower in the
high exposure group in weeks 0-8 and the positive
control group in the weeks 0, 1, and 7. This effect in
the VDC highest exposure group was, however,
probably due to infertility of the males used.
Pregnancy Frequency. The numbers of
females in each group which became pregnant at
each week ofmating are shown in Tables 3 and 9. In
the VC study, statistical differences between
treated groups and the negative control group were
found only in the EMS-treated group at weeks 1 and
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there were significant differences in the highest
VDC exposure group at weeks 0-6 and the positive
control group in weeks 0, 1, and 7. Again this was
probably due to infertility of the males.
These results indicate that VC at the three ex-
posure levels and VDC at least at exposures of 10
and 30 ppm did not cause a reduction in fertility.
Any reduced fertility at 50 ppm VDC was un-
proven.
Total Implantations
The mean total number of implants per pregnant
female in each group is shown in Tables 4 and 10.
The mean values were adjusted to take account of
the unequal number of pregnant females per male
and were compared statistically by using an
analysis of variance and a t-test. In the VC study
statistically significant differences were evident in
week 1 in the CTX-treated group and weeks I and 2
in the EMS-treated group. A significant difference
(p < 0.05) in week 4 was also found between the
group exposed to the highest dose of VC (Group 4)
and the negative control group. In the VDC study
the CTX positive control group was statistically
significantly different from the negative control
groups in weeks 1, 2, 3, 6, and 7. Only the VDC
group to be exposed to 10 ppm showed a significant
difference from the negative control group in the
pre-experimental nontreatment week.
Thus there was no indication ofa preimplantation
loss of eggs in either study except in week 4 after
30,000 ppm of VC.
Early Deaths
The data for early deaths have been presented in
various ways.
Number of Pregnant Females with One or
More Early Deaths. In the VC study, CTX and
EMS treatment caused increases in the number of
pregnancies with early deaths (Table 5). The effect
was significant (chi-square) in weeks 1 and 2 for the
CTX-treated group and in week 2 for the EMS-
treated group. No differences from the negative
control group were seen in the VC-treated group.
Similarly in the VDC study there were only sig-
nificant differences in the CTX positive control
group in weeks 1, 2, and 3 (Table 11).
The Mean Number of Early Deaths per
Pregnancy. A large number oflow or zero values
were encountered, so it was necessary to stabilize
the variance prior to analysis. There were no statis-
tically significant increases in early deaths after VC
treatment (Table 6). However, differences were
evident in weeks 1 and 2 with CTX treatment and
with EMS treatment. In the VDC study only the
CTX positive control group was significantly dif-
ferent from the negative control group in weeks 1,
2, and 3 (Table 12).
Early Deaths as a Percentage of Total Im-
plants per Pregnant Female. Again, it was
necessary to stabilize the variance prior to analysis.
In the VC study CTX and EMS treatment groups
were significantly different from the negative con-
trol groups in weeks 1 and 2, whereas VC-treated
groups were not (Table 7). The CTX treatment
group also showed a significant difference in the
week before treatment. In the VDC study only the
CTX treatment group was significantly different
from the negative control group in weeks 1, 2, and 3
(Table 13).
Thus with all these different methods ofanalysis
ofthe data ofearly deaths no statistically significant
differences from the negative control groups were
seen in the VC or VDC treated groups.
Late Deaths
In each study late deaths were randomly distrib-
uted throughout all the groups and did not appear to
be treatment-related.
Conjoined Placentae
Conjoined placentae were seen in this strain.
They were the result of very close implantation
sites and were not monozygotic twins (12). In the
experiments they were classified as double implan-
tations. Since they occurred with equal frequency
in all groups they did not appear to be correlated
with treatment.
Discussion
The best indication of mutagenic activity of a
substance in the dominant lethal test is an increase
in the number of post-implantational foetal early
deaths (13). From the data for early deaths there
was no evidence in either study of a mutagenic ef-
fect with VC or VDC at the administered exposure
levels. This did not appear to be a result of lack of
sensitivity of the animals used, since there was a
marked response to CTX and EMS. High doses of
CTX and EMS were used in our studies to obtain a
highly significant positive result. However, the
dominant lethal study in our hands (14) is at least as
sensitive as that reported elsewhere. We have shown
ethyl methane sulfonate on previous occasions to
give a positive result with a single IP dose of 150
mg/kg body weight, which is comparable to that
reported previously (15) for the same mouse strain.
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evaluation methods were used for the early deaths'
data and much of the data in the studies were sub-
jected to various methods of statistical analysis.
Pre-implantation egg losses, while representing
some of the mutagenic effect, are not as important
as postimplantational losses, for they could also
arise due to other than genetic factors (13). Pre-
implantational egg losses have been studied by
comparing values oftotal implants in females mated
with treated males and those mated with control
males, as suggested by Epstein (16), rather than
counting corpora lutea. There was no pre-
implantational egg loss by comparison of VC- or
VDC-treated groups with the negative control
group, except in the highest VC exposure group in
week 4 (p < 0.05). When a treatment group is sig-
nificantly different from a negative control group
there is generally a uniform reduction in implants,
whereas in week 4 after VC treatment the low result
was due to a large extent to the result from one
female. Without this female, mean values would not
have been significantly different from the negative
control group. Therefore, this result is not con-
sidered biologically significant. Yet another reason
is that there was no corresponding increase in early
deaths at this time.
Late deaths also are not considered as important
as early deaths in the assessment of the mutagenic
potential of a test substance (13). Late deaths were
excluded from analysis to increase test sensitivity.
Gropp and Kolbus (17) have shown, however, that
trisomies in mouse foetuses cause death and elimi-
nation before term. It might be argued that sampling
for late deaths at a later stage of pregnancy might
lead to different results for late deaths. However,
the randomness of their distribution in both studies
would suggest otherwise.
There was no reduction in fertility as measured
by the mating and pregnancy frequency at any week
at the exposure levels of VC, suggesting no antifer-
tility effect. The same was true for the VDC groups
exposed at 10 and 30 ppm. However, the decreased
fertility in the group exposed to 50 ppm was proba-
bly due to the infertility of the males which had to
be used to establish a group of sufficient size to
perform the experiment.
A fertility study was undertaken prior to the ex-
periment also for reasons described earlier (10, 11).
From these initial fertility data the background
dominant lethality of all groups was determined
primarily to ascertain that there were no initial dif-
ferences between groups.
Mutagenic effects ofvinyl chloride have been ob-
served in laboratory tests and in exposed workers.
In this study where exceptionally high doses of VC
were used, which would never be encountered by
workers, no mutational effect in the germ cells was
observed. A possible explanation is that the active
metabolites did not reach the germ cells. Similarly
the lower but more toxic levels of VDC did not
produce germ cells mutations.
It can be concluded, therefore, that VC and
VDC do not cause dominant lethal mutations in
male CD-1 mice at 3000, 10,000, and 30,000 ppm
and 10, 30, and 50 ppm, respectively.
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